SCHEMBL3929267

SCHEMBL3929267

O=C(Nc1cn(C2CCCCO2)nc1-c1nc2cc(OCCCCN3CCCCC3)c(F)cc2[nH]1)N1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.35
CHEK2 O96017 2/20 0.34
ABL1 P00519 1/20 0.33
F2 P00734 1/20 0.32
F10 P00742 1/20 0.32
PLG P00747 1/20 0.32
PLAU P00749 1/20 0.32
PLAT P00750 1/20 0.32
ITK Q08881 2/20 0.32
SYK P43405 1/20 0.32
AXL P30530 3/20 0.32
FLT1 P17948 3/20 0.32
FGFR1 P11362 2/20 0.32
IRAK4 Q9NWZ3 2/20 0.32
PDGFRB P09619 3/20 0.31
STK10 O94804 2/20 0.31
CSF1R P07333 2/20 0.31
KIT P10721 2/20 0.31
FLT4 P35916 2/20 0.31
FLT3 P36888 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3934547 0.90 ITK (0.46) EPHX2CHEK2ABL1ITKSYK
SCHEMBL13737034 0.88 ABL1 (0.34) CHEK2ABL1ITKSYKAXL
SCHEMBL18833302 0.88 ABL1 (0.34) CHEK2ABL1ITKSYKAXL
SCHEMBL13374026 0.88 HSD17B10 (0.39) ABL1ITKSYKLMNATP53
SCHEMBL3928475 0.87 ABL1 (0.34) CHEK2ABL1ITKSYKAXL
SCHEMBL3935957 0.86 CHEK2 (0.40) EPHX2CHEK2F2F10PLG
SCHEMBL3923229 0.86 SYK (0.42) EPHX2CHEK2ABL1ITKSYK
SCHEMBL3934575 0.85 SPIN1 (0.35) CHEK2F2F10PLGPLAU
SCHEMBL4004619 0.84 LMNA (0.32) ABL1ITKSYKAXLPDGFRB
SCHEMBL3935602 0.83 FLT3 (0.34) EPHX2ABL1ITKSYKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041119-B1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA SA (FR) 2017-05-10 EP disclosed
US-9126969-B2 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2015-09-08 US disclosed
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2009-08-06 US disclosed
EP-2041119-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF Aventis Pharma S.A. (FR) 2009-04-01 EP disclosed
WO-2008003857-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF RB1, CCNI, CDK2 EPHX2 3420/4885CHEK2 13/4885ABL1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.